Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics by Yang, D et al.
Theranostics 2020, Vol. 10, Issue 8 
 
 
http://www.thno.org 
3684 
Theranostics 
2020; 10(8): 3684-3707. doi: 10.7150/thno.41580 
Review 
Progress, opportunity, and perspective on exosome 
isolation – efforts for efficient exosome-based 
theranostics 
Dongbin Yang1#, Weihong Zhang2#, Huanyun Zhang1, Fengqiu Zhang3, Lanmei Chen4, Lixia Ma5, Leon M. 
Larcher6, Suxiang Chen6, Nan Liu7, Qingxia Zhao8, Phuong H.L. Tran9, Changying Chen10, Rakesh N 
Veedu6,11, Tao Wang2,6,11 
1. Department of Neurosurgery of Hebi People's Hospital; Hebi Neuroanatomical Laboratory, Hebi, 458030, China. 
2. School of Nursing, Zhengzhou University, Zhengzhou, 450001, China. 
3. Henan Key Laboratory of Ion-beam Bioengineering, Zhengzhou University, Zhengzhou, China, 450000. 
4. Guangdong Key Laboratory for Research and Development of Nature Drugs, School of Pharmacy, Guangdong Medical University, Zhanjiang 524023, 
China. 
5. School of Statistics, Henan University of Economics and Law, Zhengzhou 450046, China. 
6. Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth 6150, Australia. 
7. General Practice Centre, Nanhai Hospital, Southern Medical University, 528244, Foshan, China. 
8. School of Medicine, Wake Forest University, Winston Salem, NC 27101, USA.  
9. School of Medicine, and Centre for Molecular and Medical Research, Deakin University, 3216, Australia. 
10. The First Affiliated Hospital of Zheng Zhou University, Zhengzhou 450001, China. 
11. Perron Institute for Neurological and Translational Science, Perth 6009, Australia 
#These authors contribute equally to this work. 
 Corresponding author: Tao Wang, wangtaomary@zzu.edu.cn; Rakesh N Veedu, R.Veedu@murdoch.edu.au; Changying Chen, changying@zzu.edu.cn. 
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). 
See http://ivyspring.com/terms for full terms and conditions. 
Received: 2019.10.29; Accepted: 2020.02.08; Published: 2020.02.19 
Abstract 
Exosomes are small extracellular vesicles with diameters of 30–150 nm. In both physiological and 
pathological conditions, nearly all types of cells can release exosomes, which play important roles in 
cell communication and epigenetic regulation by transporting crucial protein and genetic materials 
such as miRNA, mRNA, and DNA. Consequently, exosome-based disease diagnosis and therapeutic 
methods have been intensively investigated. However, as in any natural science field, the in-depth 
investigation of exosomes relies heavily on technological advances. Historically, the two main 
technical hindrances that have restricted the basic and applied researches of exosomes include, first, 
how to simplify the extraction and improve the yield of exosomes and, second, how to effectively 
distinguish exosomes from other extracellular vesicles, especially functional microvesicles. Over the 
past few decades, although a standardized exosome isolation method has still not become available, 
a number of techniques have been established through exploration of the biochemical and 
physicochemical features of exosomes. In this work, by comprehensively analyzing the progresses in 
exosome separation strategies, we provide a panoramic view of current exosome isolation 
techniques, providing perspectives toward the development of novel approaches for high-efficient 
exosome isolation from various types of biological matrices. In addition, from the perspective of 
exosome-based diagnosis and therapeutics, we emphasize the issue of quantitative exosome and 
microvesicle separation. 
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1. Exosomes and two obstacles for 
exosome-based basic and applied 
investigations 
The physiological function of the human body 
relies on effective and precise cell communication [1]. 
Apart from contact-dependent and soluble molecule- 
mediated signal transduction, we have expanded our 
knowledge of cell communication in recent years to 
include the role of exosomes as a new form of 
signaling system [2]. Exosomes are small extracellular 
vesicles with diameters between 30–150 nm that 
feature a double-layer lipid membrane structure. 
Exosomes can be produced by almost all kinds of cells 
under both physiological and pathological conditions, 
and are widely distributed through easily accessible 
body fluids such as blood, saliva, breast milk or urine. 
The discovery of exosomes was first reported in 1987 
[3]. For many years, exosomes were assumed to be 
“junk” produced during the maturation process of 
cells [3]. However, with the recent isolation of various 
proteins, lipids and genetic materials (e.g., miRNA, 
mRNA, DNA molecules as well as long-noncoding 
RNAs) from different types of exosomes [4], their 
crucial roles in cell communication and epigenetic 
regulation have been recognized [2]. Importantly, 
whether under pathological or physiological condi-
tions, exosome contents are finely regulated by their 
parental cells to pass information from the parental 
cells to other cells for specific functions [5]. In turn, the 
functional states of the parental cells can be estimated 
by analyzing their exosome contents [5], which lays 
the foundation for exosome-based diagnosis, 
especially non-invasive liquid biopsy. Apart from in 
disease diagnosis, exosome application also features 
in various biomedical fields including drug delivery 
[6], cell-free vaccine development [7], and regenera-
tive medicine [8]. Recently, the application of exo-
somes as a potent substitute for maternal cells in 
immunotherapy and regenerative medicine has been 
demonstrated with in vivo animal work, serving as the 
basis for several ongoing clinical studies [9]. Indeed, 
exosomes hold high potential in the treatment of 
various diseases; by 2018 exosome-related investiga-
tions attracted $250 million (USD) in investments and 
are expected to exceed $1 billion (USD) by 2021 [10]. 
Accordingly, there are currently 127 exosome-related 
clinical trials being registered at Clinicaltrials.gov 
(versus 26 trails for the year of 2017) involving treat-
ment and diagnosis of multiple types of diseases. 
Considering that the key discovery of genetic material 
in exosomes was not published until 2007 [2], the 
speed of clinical translation of exosome-based thera-
nostics has far exceeded the original expectations [9]. 
However, the general atmosphere around 
exosome-based clinical application is still pessimistic. 
As addressed by a recent position paper of the 
International Society for Extracellular Vesicle (ISEV) 
[9], the explosive attention and substantial capital 
investment in clinical translation of exosomes is 
mainly due to open intellectual property space, which 
provides incentive for early movers. Whether these 
efforts are successful depends on the solution of 
several key technical issues, as historically, there have 
been two main technical hindrances that restrict the 
basic and applied researches of exosomes [11]. The 
first is how to simplify the exosome extraction 
procedure and improve the yield of exosomes; the 
second is how to effectively distinguish exosomes 
from other extracellular vesicles, especially from 
functional microvesicles.  
In this work, by comprehensively analyzing 
existing exosome isolation techniques, we provide 
suggestions and insights for future exosome 
separation methods and related applications. In 
addition, from the perspective of exosome-based 
diagnosis and therapeutics, we also emphasize the 
issue of quantitative exosome and microvesicle 
separation. 
2. Six major separation strategies 
exploring different physiochemical 
properties of exosomes 
Exosomes are nano-sized extracellular vesicles 
distributed through vastly complex body fluids, 
which makes high-yield exosome isolation challeng-
ing [12]. For instance, although ultracentrifugation 
has been the “gold standard” for exosome separation 
due to its high processing capacity, high levels of 
protein aggregate and lipoprotein contamination in 
exosome samples prepared through this method 
greatly compromises their quantification and funct-
ional analysis [13]. Because a single method fitting a 
variety of sample sources is not practicable, efforts 
have been made to exploit different physiochemical 
and biochemical properties of exosomes. Until now, 
six classes of exosome separation strategies have been 
reported, including ultra-speed centrifugation, ultra-
filtration, immunoaffinity capture, charge neutraliza-
tion-based polymer precipitation, size-exclusion chro-
matograph, and microfluidic techniques, with unique 
sets of advantages and disadvantages for each tech-
nique (Table 1). In this section, by analyzing 
principles, procedures, and advantages and disad-
vantages of individual techniques, we provide a 
panoramic view of current exosome isolation strat-
egies. This overview not only facilitates the optimiza-
tion of exosome isolation strategies in different appli-
cations, but also provides new outlooks for the 
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development of novel devices and approaches for 
efficient exosome isolation. 
Importantly, as we will discuss in Section 3, 
although vesicles prepared by current approaches are 
commonly denoted as exosomes, it should be noted 
that the term “exosome” is often used improperly in 
published articles or clinical trials. Apart from 
exosomes, the “exosome samples” prepared via 
current techniques also include a great number of 
non-exosome vesicles such as microvesicles, apoptotic 
bodies and ectosomes [11, 14]. This is because of their 
vast overlap in physicochemical properties and the 
currently limited knowledge about the molecular 
mechanisms of exosome biogenesis and release. Such 
non-exosome particles, especially functional micro-
vesicles, compromise the accuracy and reliability of 
exosome-based theranostics. For this reason, the 2018 
ISEV guideline position paper has suggested that due 
to the lack of pure exosome separation with current 
techniques, the commonly used term of exosome 
should be replaced with the more collective term of 
extracellular vesicle [15]. As a result, unless specifi-
cally stated, the term “exosome” used in this article 
denotes a mixture of small extracellular vesicles such 
as exosomes, apoptotic bodies, microparticles, 
microvesicles, ectosomes, as well as oncosomes. 
2. 1 Ultracentrifugation-the gold standard 
exosome isolation approach 
With the capacity to generate centrifugal forces 
as high as 1,000,000 ×g (100,000–150,000 ×g is 
commonly used for exosome separation), ultracentri-
fugation is an optimal process for separating small 
particles including bacteria, viruses, and cellular 
organelles. As such, ultracentrifugation readily trans-
lates to exosome isolation and has contributed to 
many pioneering exosome explorations [3, 16]. We 
will next discuss the application and main features of 
three common ultracentrifugation methods to 
demonstrate the details of this “gold standard” 
exosome isolation strategy. 
 
Table 1. Current strategies for exosome separation 
Isolation technique Principle Advantages Disadvantages 
Sequential ultracentrifugation Particles have different 
density and size show 
different sediment speed 
under centrifugal force  
• Low cost and 
• Low contamination risk with extra isolation 
reagents; 
•suitable for large volume preparation;  
• High equipment requirement 
• Time consuming 
• Labor intensive 
• Potential mechanical damage due to high speed 
centrifugation 
• Protein aggregation 
• Not suitable for small volume diagnosis 
• Low portability 
Gradient ultracentrifugation After centrifugation in a 
dense medium, objects in 
a tube could stay in the 
position of the medium 
with similar density  
• High purity of products 
• Allowing separation of subpopulation of 
exosomes 
• Lower volume processability 
• High equipment requirement 
• Time consuming 
• Labor intensive 
• Potential mechanical damage due to high speed 
centrifugation 
• Not suitable for small volume diagnosis 
• Low portability 
Ultrafiltration Utilizing filter membrane 
with defined 
size-exclusion limit or 
molecular weight cut-off 
• Low equipment cost 
• Fast procedure 
• good portability 
• Moderate purity 
• Potential deterioration induced by shear stress 
• Possible loss due to clogging and membrane 
trapping  
Size-exclusion chromatography After adding to porous 
materials, substances 
eluted out in accordance 
with their particle size, 
with big particles eluted 
earlier  
• High purity 
• Fast preparation 
• Keep native state of exosomes 
• Good reproducibility 
• Potential for both small and large sample 
capacity;  
• Capable of processing all type of samples 
• Relatively high device costs 
• Additional method for exosome enrichment is 
required 
Polymer Precipitation High hydrophilic 
water-excluding 
polymers can alternate 
the solubility of exosomes  
• Easy to use 
• Using ordinary equipment 
•Suitable for both small and large sample 
volume 
• High efficiency 
• Contaminants of protein aggregates, other 
extracellular vesicles and polymeric contaminants 
• Extended processing time 
• Require complicated clean-up steps 
• Affecting downstream analysis and 
quantification 
Immunoaffinity capture Based on specific binding 
between exosome 
markers and immobilized 
antibodies (ligands) 
• Suitable for separating exosomes of specific 
origin; 
• High-purity exosomes 
• Easy to use 
• No chemical contamination  
• High-cost antibodies; 
• Exosome markers must be optimized 
• Low processing volume and yields 
• Extra step for exosome elution may damage 
native exosome structure 
Microfluidics-based techniques Based on different 
principles including 
immunoaffinity, size and 
density 
• Highly efficient 
• Cost-effective 
• Portable 
• Easily automated & integrated with 
diagnosis 
• Low sample capacity 
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2.1.1 Differential ultracentrifugation contributed to 
most pioneering exosome studies 
Differential ultracentrifugation, also referred to 
as simple ultracentrifugation or the pelleting method, 
is the most commonly reported strategy for exosome 
separation (45.7%) [17,18]. The principle of differential 
ultracentrifugation is quite simple – under certain 
centrifugal forces, different extracellular components 
of a fluidic sample can be sequentially separated 
based on density, size as well as shape. This method 
was first reported by Johnston in 1987 to isolate 
exosomes from the culture medium of reticulocyte 
tissue [16]. Later, in 2006, differential ultracentrifu-
gation was further optimized by Thery and colleagues 
with a set of increasing centrifugal forces [19]. As 
demonstrated in Figure 1, depending on the nature of 
the tested samples, a cleaning step may be first 
conducted to eliminate large bio-particles by low- 
speed centrifugation (e.g., 300 ×g), followed by 
multiple cycles of centrifugation with centrifugal 
force from 2000 ×g up to 100,000 ×g, to sequentially 
remove contaminants such as cell derbies, apoptotic 
bodies and protein aggregates for purified exosome 
isolation. Importantly, this method easily scales up for 
large scale exosome preparation. Although commonly 
used ultracentrifugation tubes have a relatively low 
volume capacity (~5–20 mL), existing liquid concen-
tration devices (e.g., Centricon® Plus-70 Centrifugal 
Filter Units) [6] can facilitate the process of volumes of 
up to 200 mL with a 5-mL loading capacity 
ultracentrifugation tube. 
Due to ease of use, little technical expertise 
requirement, and compatibility with large volume 
preparation without complicated sample pre- 
treatment, differential ultracentrifugation has been 
widely employed over the past 30 years to isolate 
exosomes from various sources such as cell culture 
medium, serum, saliva, urine, and cerebrospinal fluid 
[6, 20-22]. However, it should be noted that extra-
cellular fluids feature high heterogeneity. Under a 
certain centrifugal force, all components (including 
exosomes, microvesicles, and non-vesicles such as 
protein aggregates and lipoproteins) with buoyant 
density, size, and mass reaching a certain threshold 
can be precipitated at the bottom of the tube [23]. 
Therefore, exosome samples prepared via differential 
ultracentrifugation often suffer from low purity, 
which potentially compromises many downstream 
applications, especially exosome-associated func-
tional analysis [24]. For example, in a well-designed 
comparison study, Paolini and colleagues used 
several different strategies to separate exosomes from 
the blood of patients suffering from multiple mye-
loma. In the subsequent functional study, they 
observed that exosomes prepared with differential 
ultracentrifugation (displayed high-amount contami-
nation) demonstrated only poor and inconsistent 
biological functions compared to more purified 
exosome samples, which could induce prominent 
NF-κB nuclear translocation in endothelial cells [25]. 
Fortunately, to further improve the exosome 
isolation efficiency of this classical separation tech-
nique, various types of centrifugation strategies have 
been developed during the past two centuries 
through the exploration of the different physical 
properties of objects. Among these strategies, a widely 
used method is density-gradient centrifugation, 
which separates particles by density [26-28]. 
2.1.2 Isopycnic & moving-zone density-gradient 
ultracentrifugation for high-quality exosome isolation 
In 1937, Linderstorm-Lang discovered that after 
centrifugation in a density-gradient tube, objects of a 
particular density would remain suspended in 
medium of a similar density [29]. Historically, the 
density-gradient-based centrifugation method has 
been commonly used in hematological study for the 
separation of subpopulations of blood cells, due to the 
differences in density of different cell types [30]. Simi-
larly, due to the density differences between different 
extracellular components, purified exosomes can be 
obtained through this method [31, 32]. A typical 
density-gradient ultracentrifugation includes the 
following steps: First, layers of biocompatible med-
ium with varying densities (e.g., iodoxinol or sucrose) 
covering the range of particle densities in the sample 
is placed into a tube, with gradually decreasing 
densities from bottom to top (Figure 2A). Next, the 
sample of interest is added onto the top of the density- 
gradient medium, followed by extended centrifuga-
tion for a prolonged period (e.g., 100, 000 ×g for 16 h) 
[6, 33]. Eventually, the extracellular components, 
including exosomes, apoptotic bodies, and protein 
aggregates, gradually reach a static position (isopyc-
nic position) in the layer of the same density. Through 
this method, components having different buoyant 
densities can be easily separated; protein aggregates 
concentrate at the bottom of the centrifugation tube 
while exosomes remain in the layer of medium bet-
ween 1.10 and 1.18 g mL−1 [34]. Again, in reference to 
Paolini and colleagues’ comparison study [25], comp-
ared with differential ultracentrifugation and popular 
one-step precipitation kits (to be discussed in Section 
2.4); density-gradient ultracentrifugation achieves the 
purest exosome samples for downstream applica-
tions. As a result, density-gradient ultracentrifugation 
has gained great popularity in recent years for 
exosome separation, representing around 11.6% of the 
currently used exosome strategies [17, 25]. 
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Figure 1. Schematic representation of differential ultracentrifugation-based exosome isolation. Differential ultracentrifugation is performed by 
multiple cycles of centrifugation with centrifugal forces from 300 ×g up to 100,000 ×g. After each centrifugation step, pellets including cells, cell debris as well as 
apoptotic bodies are removed while the supernatant was collected for further centrifugation. After the last centrifugation (i.e., 100,000 ×g), exosomes-containing 
pellets and contaminant proteins are collected by removing the supernatant. The centrifugation is performed at 4°C. 
 
Figure 2. Schematic representative of gradient density ultracentrifugation-based exosome isolation. (A) Isopycnic density-gradient ultracentrifugation 
is prepared by adding medium in layers of progressively decreased density from bottom to top. After prolonged centrifugation, extracellular components including 
exosomes, apoptotic bodies and protein aggregates reach a static position in medium of similar density to each component. However, because isopycnic gradient 
ultracentrifugation depends solely on the density difference between different solutes in samples, this method cannot separate substances (e.g., microvesicles) with 
similar buoyant density to exosomes. (B) The moving-zone gradient ultracentrifugation normally consists two gradient medium sections. The top layer is a medium 
with density lower than all of the solutes of the sample. The bottom is a high-density cushion. As the density of the solutes are all greater than that of the gradient 
medium, after centrifugation, all solutes will be sequentially separated based on not only density, but also mass/size, thereby allowing the separation of vesicles of 
comparable density but varying size. 
 
However, such commonly used isopycnic 
ultracentrifugation depends entirely on the density 
difference between different solutes in samples. 
Although this method effectively separates exosomes 
from common contaminants such as protein aggre-
gates, this method cannot separate extracellular 
vesicles with similar buoyant density (but different 
size) to exosomes (e.g., microvesicles) [35]. To 
effectively address this technical issue, studies have 
used moving-zone density-gradient centrifugation 
(also termed as rate zonal centrifugation), which 
separates particles by both size and density [36]. As 
shown in Figure 2B, the moving-zone ultracentrifuge-
tion features a medium with a density lower than that 
of all solutes in the sample. As the density of the 
solutes is greater than that of the gradient medium, 
after centrifugation, all solutes in the sample will be 
sequentially separated based on not only density, but 
also mass/size, thereby allowing the isolation of 
vesicles with comparable densities but varying sizes 
(e.g., exosomes, viruses and large microvesicles) [36]. 
However, unlike isopycnic ultracentrifugation, be-
cause the concentration of the medium in this type of 
ultracentrifugation is lower than that of all sample 
components, all insoluble particles can be pelleted at 
the bottom of the tube after prolonged centrifugation 
(hence why it is called moving-zone centrifugation). 
Consequently, the centrifugation time must be care-
fully determined for optimal exosome isolation. In 
order to minimize exosome pelleting, a high-density 
medium is normally loaded in the bottom of the 
centrifuge tube to serve as a cushion (Figure 2B). 
Despite various advantages and wide appli-
cation, ultracentrifugation does have its short-
comings. For instance, although gradient ultracentri-
fugation is capable of purifying exosomes with 
minimal contamination, the processing volume of this 
method is limited by the thin loading zone [13]. 
Additionally, ultracentrifugation approaches require 
not only expensive equipment, but also highly trained 
technicians, especially for gradient ultracentrifu-
gation. Furthermore, as has been emphasized by 
previous studies [37], the structure and biological 
function of the isolated exosomes can be detrimentally 
affected by prolonged periods of ultra-centrifugal 
force, which is very unfavorable for downstream 
applications such as exosome-based functional 
studies and drug development. In light of this issue, 
other size-based separation strategies such as ultra-
filtration and size-exclusion chromatography have 
been introduced. As we discuss in the next sections, 
various simplified and highly efficient exosome 
Theranostics 2020, Vol. 10, Issue 8 
 
 
http://www.thno.org 
3689 
separation kits based on such techniques are now 
commercially available. 
2.2 Ultrafiltration holds potential for industrial 
scale exosome preparation 
Similar to conventional filtration methods, 
ultrafiltration uses an ultrafine Nano-membrane with 
different MWCO (molecular weight cut-off) to isolate 
extracellular vesicles from clinical samples or cell 
culture medium and differentiate between exosomes 
and co-vesicles by size [38]. Compared with the ultra-
centrifugation method, ultrafiltration-based exosome 
isolation dramatically shortens processing time and 
does not require special equipment, presenting an 
ideal substitute to the classical ultracentrifugation 
strategy [39]. Importantly, by easily adjusting filter 
size, ultrafiltration allows researchers to sort specific 
subsets of small extracellular vesicles (including 
exosomes) with defined particle sizes [40]. 
Based on this principle, several simplified and 
easy-to-use ultrafiltration devices have been recently 
developed to facilitate the fast preparation of exo-
somes with yield comparable to that of the ultra-
centrifugation method [40]. As demonstrated in 
Figure 3, there are two types of ultrafiltration devices 
that have been well-developed. The first is a tandem- 
configured microfilter (Figure 3A), which consists of 
two tandem-configured microfilters with defined 
size-exclusion limits around 20–200 nm [41]. When 
passed through the two membranes, large vesicles 
including apoptotic bodies, as well as the majority of 
microvesicles; are trapped in the 200-nm membrane 
whilst vesicles of 20–200 nm diameter remain on the 
bottom and smaller particles such as proteins pass 
through the 20-nm microfilter. On the other hand, 
sequential ultrafiltration is another popular method 
for exosome isolation (Figure 3B) [42]. In this mode, 
extracellular fluids are first passed through a 1000-nm 
filter to get rid of large particles including cell debris, 
cells, and apoptotic bodies. After that, the filtrate is 
then passed through a second filter with 500-kD 
MWCO to remove free proteins and other small 
particles. Finally, exosomes with diameters between 
50–200 nm can be collected from the filtrate with a 
200-nm filter. Based on this sequential ultrafiltration 
protocol, the Bio Scientific Corporation recently 
developed a kit called “ExoMir™ exosome isolation” 
[43]. By leveraging a syringe filter-based adjustable 
fractionation process, this device enables large 
volume processing (10–25 mL/run), rapid isolation of 
small extracellular vesicles (including exosomes and 
microvesicles depending on filter size) from various 
types of fluids include serum, cerebrospinal fluid, and 
eukaryotic cell culture media. In addition, by 
including a second RNA isolation module, this kit 
allows real-time RNA isolation from the harvested 
small extracellular vesicles for further analysis. 
Over the past decade, due to high efficiency 
(minutes for ultrafiltration vs up to 16h for ultra-
centrifugation) and simplicity (does not require 
special equipment), ultrafiltration gained increasing 
popularity, representing around 5.4% of the currently 
used exosome isolation methods [17]. However, this 
method has a few limitations. One of the most 
noticeable problems associated with the application of 
ultrafiltration is vesicle clogging and trapping, which 
potentially reduces the lifetime of the expensive 
membranes and leads to low separation yield [44, 45]. 
Apart from pre-treatment with proteinase to reduce 
fluid sample viscosity [46, 47], tangential flow 
filtration techniques present an ideal solution to this 
problem [48]. As demonstrated in Figure 4, during 
tangential flow filtration, the feed stream flows 
parallel to the membrane [49]. Through manipulation 
of the hydrodynamic flow force, the pressure applied 
to the flow stream causes only part of the flow to cross 
the membrane. As the membrane is constantly under 
a parallel flow force, potential clogging can be 
efficiently minimized (via constant flushing). The 
remainder (retentate) can then be re-circulated back to 
the feed reservoir for repeated filtration during the 
tangential flow filtration procedure, thus allowing an 
automated procedure as well as high yield [50]. 
Tangential flow filtration-based exosome preparation 
has been applied to separate exosomes for various 
clinical trials due to these advantages [38, 51, 52]. In a 
recent clinical trial, dendritic cell-derived exosomes 
prepared by this method were able to effectively 
promote T-Cell response in a promising anti-cancer 
treatment [53]. In 2017, the University of Texas MD 
Anderson Cancer Centre developed a notable three- 
step sequential filtration device designed for process-
ing large volumes of bio-fluids based on tangential 
flow technique [40]. The exosome isolation device 
consists of three separate modules where first, large 
particles such as cell debris are filtered out by a 100- 
nm filter which detains only inflexible solutes with 
sizes larger than 100 nm such as apoptosis bodies but 
allows flexible solutes to cross, even if they are larger 
than 100 nm in size. Next, tangential flow filtration is 
performed using 500-kDa MWCO hollow fibers to 
further deplete small contaminants such as proteins. 
Lastly, exosomes are isolated by filtering the retentate 
through a low-pressure filter with defined pore size 
(i.e., 100 nm). In addition to its fast processing, 
simplified procedure and isolation of exosomes with 
defined particle size, this semi-automated ultrafiltra-
tion strategy allows the isolation of extracellular vesi-
cles on an industrial scale with minimum structural 
damage (maintaining functional integrity) via careful 
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monitoring and maintenance of the transmembrane 
pressure, therefore holding great potential for 
exosome-based theranostic translations. 
Apart from vesicle clogging and trapping, the 
co-presence of nanoparticles with sizes comparable to 
those of exosomes presents another limitation of 
ultrafiltration [54]. The combination of two or more 
isolation methods (e.g., gradient ultracentrifugation) 
can address this problem [55, 56]. Importantly, the 
transmembrane pressure applied during ultra-
filtration, if performed improperly, could detriment-
ally affect the native state of the isolated exosomes, 
resulting in loss of function [42]. For this reason, 
caution needs to be taken during the whole ultrafil-
tration procedure to avoid the collected exosomes 
from deformation and fragmentation [57, 58]. 
2.3 Size-exclusion chromatography allows 
separation of exosomes with minimal 
structural damage 
In 1955, Grant H.L and Colin R.R invented a 
size-based separation technique termed size-exclusion 
chromatography (SEC) to isolate solutes of different 
molecular weights by passing aqueous solution 
through a column made of starch and water [59]. 
When passing a liquid sample through a stationary 
phase consisting of porous particles, molecules with 
different hydrodynamic radii submitted to different 
fates. While molecules smaller than the pores of the 
stationary phase are slowed because they enter into 
the pores, larger molecules, which cannot enter the 
pores are forced around the porous particles and are 
eluted earlier from the column (Figure 5). Over the 
past 50 years, this method was dramatically improved 
through the introduction of various fine, porous 
materials such as dextran polymer (Sephadex), aga-
rose (Sepharose), and polyacrylamide (Sephacryl or 
BioGel) [60]. Long before the discovery of exosomes, 
SEC has been well-developed and widely applied to 
the high-resolution separation of large molecules or 
aggregates of macromolecules such as proteins, poly-
mers, and various liposome particles [60-62]. The 
knowledge acquired from SEC-based liposome isola-
tion translates readily to exosome separation, as exo-
somes share many similar physical properties with 
liposomes. In merely 10 years of development, 
companies have developed various commercial SEC 
kits designed specifically for exosome isolation such 
as qEV (iZON) and PURE-EVs (Hansa Biomed). 
 
 
Figure 3. Schematic demonstration of ultrafiltration-based exosome separation. (A) Tandem- configured microfilter. Extracellular fluids are passed 
through tandem-configured microfilters with defined size-exclusion limits around 20–200 nm. When passing through the two membranes, large vesicles including cell 
debris, apoptotic bodies and the majority of microvesicles are trapped in the 200-nm membrane, while vesicles with diameter from 20 to 200 nm are retained on the 
lower 20 nm filter. (B) Sequential ultrafiltration. Extracellular fluids are first passed through a 1000-nm filter to get rid of larger particles (e.g., cells or cell debris); then 
the filtrate is passed through a second filter with 500-kD cut-off to remove small particles such as free proteins; finally, exosomes <200 nm are collected via a 200-nm 
filter. 
 
Figure 4. Tangential flow filtration ensures highly efficient ultrafiltration. During tangential flow filtration, the feed stream flows parallel to the membrane 
face. The applied pressure causes one portion of the flow stream to pass through the membrane according to the filter size. As the membrane is constantly under a 
parallel flow force, potential clogging can be efficiently minimized. During the tangential flow filtration procedure, the remainder is re-circulated back to the feed 
reservoir for repeated filtration, ensuring thorough filtration. 
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Figure 5. Principle for Size-exclusion chromatography-based exosome isolation. When passing a solution through a stationary phase consisting of porous 
resin particles, molecules can be separated according to size (A); While particles with hydrodynamic radii smaller than that of the pores of the stationary phase enter 
into the pores for longer traffic distance, larger particles, which cannot enter the pores move directly around the resin (B). This causes particles with different sizes 
to exhibit different retention times and therefore facilitate size-based separation. 
 
In terms of exosome-based therapeutic applica-
tion and functional studies, perhaps the most 
appealing feature of SEC is its ability to preserve the 
natural biological activities of the separated exosomes 
[63]. Unlike ultracentrifugation and filtration, SEC is 
performed by passive gravity flow, which does not 
affect vesicle structure and integrity [58]. The natural 
state of exosomes can be further enhanced by the 
selection of elution buffers with physiological 
osmolarity and viscosity (e.g., PBS) [64]. Apart from 
maintaining exosome function, SEC has additional 
advantages. First, SEC requires minimal volumes. 
With commercially available SEC columns; volumes 
as small as 15 µL can be processed to achieve 
high-resolution, standardized, and reproducible 
exosome isolation suitable to exosome-based fingertip 
analysis [65]. Second, SEC-based exosome collection is 
simple, compatible with various types of fluids, and 
an extra pre-treatment step is generally not required 
[14]. Third, the SEC method saves time and labor. 
With selective porous materials and buffer systems, 
the whole process can be completed within a short 
and well-defined time period (e.g., 15 minutes) [66]. 
Fourth, similarly to the ultrafiltration method, fine 
adjustment of the pore size of the applied materials 
can yield a defined subpopulation of extracellular 
vesicles [66]. Lastly, compared to ultrafiltration-based 
separation, the contact-free manner of SEC (solutes do 
not interact with the stationary phases) ensures none 
or minimal sample loss and high yield [63]. Given all 
these merits, it is not surprising that in recent years’ 
SEC-based exosome isolation has becoming increa-
singly popular for exosome-based basic and clinical 
investigations. Importantly, this method is not only 
suitable for processing trace amount liquid samples, 
but also easily scalable and automated for high- 
throughput exosome preparation. Recently, iZON 
developed an automatic exosome isolation system 
(qEV Automatic Fraction Collector) based on the 
established SEC platform and weight-dependent 
segment and sample collecting systems which allows 
fast, precise, scalable and automated exosome 
isolation [67]. 
Despite various advantages, the SEC method 
also faces several challenges. According to a recent 
comparison study, exosomes prepared via SEC 
column commonly displayed wider size distribution, 
especially in the lower size range, suggesting the 
existence of contaminants with sizes similar to those 
of exosomes such as proteins aggregates and lipo-
proteins. To eliminate such contaminants, in the 2013 
ISEV conference, Gardiner proposed an exosome iso-
lation strategy by combining ultrafiltration and SEC 
[68]. Later, the combined use of ultrafiltration and 
SEC was practiced in cell culture medium by Shu and 
colleagues [69]. According to their assessment, in 
comparison with solely SEC or ultrafiltration, this 
combined strategy not only harvested exosomes with 
significantly improved purity, but also preserved 
exosome function. Similarly, functional exosomes 
were also prepared by Rood’s group via combined 
application of ultracentrifugation and SEC [70]. 
2.4 High-yield polymer precipitation strategy 
coupling with issue of contamination 
Along with the size-dependent exosome isola-
tion strategies discussed above, polymer-induced 
precipitation presents another commonly used 
strategy for exosome isolation. Analogous to ethanol- 
mediated nucleic acid precipitation, highly hydro-
philic polymers interact with water molecules 
surrounding the exosomes to create a hydrophobic 
micro-environment, resulting in exosome precipita-
tion [46]. Among various hydrophilic polymers, poly-
ethylene glycol (PEG), a well-described, non-toxic 
polymer (a common excipient for pharmaceutical 
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products) with the ability to remodel the water solu-
bility of surrounding materials has been commonly 
used [71], and constitutes the foundation for several 
popular commercial exosome isolation kits, such as 
ExoPrep (HansaBioMed, Estonia), Total Exosome 
Isolation Reagent (Invitrogen, USA), ExoQuick 
(System Biosciences, USA), Exosome Purification Kit 
(Norgen Biotek, Canada), miRCURY as well as 
Exosome Isolation Kit (Exiqon, Denmark). 
Existing polymer-based exosome precipitation 
methods generally employ PEG with molecular 
weights from 6000 to 20000 Da [71]. Firstly, a pre- 
treatment is required to remove big contaminant 
particles such as cell debris and apoptotic bodies, 
followed by incubation of the pre-treated samples 
with PEG solution at 4°C for overnight [72]. Next, the 
precipitated exosomes are collected via low-speed 
centrifugation (1500 ×g) (Figure 6). With such a 
straightforward protocol, this method has been 
widely used to isolate exosomes from various types of 
samples such as blood, cell culture medium, cerebro-
spinal fluid, urine, and ascites [46, 73, 74]. Since 
polymer precipitation methods do not require sophis-
ticated equipment, this method is easily scalable to 
large preparation volumes with high yield. This 
method also allows fast disease diagnosis through the 
integration of various detection platforms for exo-
some (or protein/genetic material contents) analysis 
[75]. 
Typically, polymer precipitation-based exosome 
isolation is characterized by high yield. As shown in a 
recent comparison study using urinary samples, 
polymer precipitation achieved the highest yield of 
exosome and genetic contents (i.e., miRNAs and 
mRNAs) for subsequent profiling analysis, compared 
to differential ultracentrifugation and ultrafiltration 
methods [55]. However, water-excluding polymers 
can precipitate not only exosomes, but also various 
water-soluble materials such as nucleic acids, 
lipoproteins, protein, and even viruses [76, 77], there-
fore the possibility of other extracellular contaminants 
could be very high. Indeed, after testing exosome 
samples collected via polymer precipitation through a 
mass spectrometry assay, noticeable detected protein 
contaminants included albumin and immunoglobu-
lin, accompanied by residue polymer molecules [78, 
79]. Currently, although various techniques (e.g., 
Nanosight particle tracking analysis, vesicle flow 
cytometry, tunable resistive pulse sensing, electron 
microscopy, and surface plasmon resonance) have 
been developed for exosome quantification, a gold 
standard exosome quantification strategy has not 
been developed. All of these strategies have their 
limitations. For instance, although Nanosight Nano-
particle Tracking Analysis has been commonly 
employed, this method is expensive and restricted to 
a limited dynamic range for particle concentration 
measurements. In most current studies, exosome 
quantification relies on the measurement of the total 
protein content of the tested samples [6, 24]. For this 
reason, polymer precipitation inevitably causes false 
quantification of exosome preparations due to the 
existence of nonspecific protein contaminations (as 
well as protein from other non-exosome particles) 
[80]. In addition, the existence of such contaminants 
may also impair downstream analysis. In a recent 
comparison study, when Girijesh and colleagues 
treated human pancreatic cancer MiaPaCa cells with 
exosomes prepared via different methods, it was 
found that exosomes prepared by precipitation rather 
than other strategies resulted in unexpected cell 
toxicity [55]. To further improve the polymer-based 
exosome preparation, apart from applying extra pre- 
clean (i.e., centrifugation) and post-clean (i.e., via 
sephadex G-25 column) steps or the combined appli-
cation of two or more techniques [71], the recently 
reported aqueous two-phase (layer) system (ATPSs) 
presents another option [81]. 
ATPS has been widely used to separate various 
substances including cells, proteins, and metal ions 
[82]. As shown in Figure 7, the principle of ATPS is 
very similar to that of the traditional organic-water 
solvent extraction system. When the relatively more 
hydrophobic solution (e.g., PEG) and more hydro-
philic and denser solution (e.g., Dextran) are mixed 
together, a two-phase system occurs, where PEG con-
sists of the upper phase while dextran forms the lower 
phase. Accordingly, after adding PEG and dextran to 
exosome-containing solutions, followed by a low- 
speed centrifugation, particles with different physico-
chemical features separate into different phases. 
While exosomes preferentially accumulate in the dex-
tran phase, proteins and other macromolecular com-
plexes preferentially accumulate into the PEG phase. 
As reported, ordinary laboratory equipment and a 
mere 15-min incubation with the ATPS method 
yielded ~70% exosome recovery efficiency, about four 
times higher than the classical ultracentrifugation 
method [17]. Despite the observation on subsequent 
PCR of the adverse effect of high biopolymer concen-
tration and high solution viscosity (e.g., up to 1.5% 
dextran) [17], this method presents a promising, inex-
pensive and rapid exosome isolation strategy to 
simplify exosome-based various applications. 
2.5 Immunoaffinity capture enables isolation of 
highly purified exosomes for in situ detection 
The observation that some proteins and recep-
tors that are common in all exosomes, regardless of 
their origin [83], provides an opportunity to develop 
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immunoaffinity-based exosome isolation via the 
binding specificity between such protein markers and 
their corresponding antibodies (or exosome receptors 
and their ligands) (Figure 8). Theoretically, any pro-
tein or cell membrane components solely or highly 
presented on the membrane of exosomes and lacking 
solvable counterparts in the extracellular fluids could 
be used for immunoaffinity-based exosome capture. 
During the past few decades, various exosome mark-
ers have been recorded including lysosome associated 
membrane protein-2B, transmembrane proteins, heat 
shock proteins, platelet-derived growth factor recep-
tors, fusion proteins (e.g., flotillins, annexins, and 
GTPases), lipid-related proteins, as well as phospho-
lipases [84-87]. Among them, transmembrane proteins 
such as Rab5, CD81, CD63, CD9, CD82, annexin, and 
Alix have been extensively exploited for selective 
exosome isolation [88, 89], resulting in several popular 
exosome isolation products including the Exosome 
isolation and analysis kit (Abcam), Exosome-human 
CD63 isolation reagent (Thermofisher) and Exosome 
Isolation Kit CD81/CD63 (Miltenyi Biotec). Remark-
ably, via specific biomarkers, immunoaffinity capture 
represents an ideal platform for isolating defined sub-
populations of exosomes with specific origins. As 
demonstrated by a previous investigation, an EpCAM 
(overexpressed on tumor derived exosomes) anti-
body-coated magnetic bead system allowed the 
specific isolation of tumor-originated exosomes from 
not only cell culture medium but also various types of 
clinical samples [90]. Recently, immunoaffinity separ-
ation systems designed for the isolation of specific 
subpopulation of exosomes have become commer-
cially available (e.g., Exosome-Human EpCAM 
Isolation Reagent, Thermofisher). Obviously, collec-
ting exosomes of specific origin not only facilitates the 
study of their parental cells, but also provides 
important indicators for disease diagnosis (for exam-
ple, via detecting EpCAM positive exosomes to assess 
the existence of EpCAM related cancers). 
2.5.1 Solid matrices for antibody immobilization 
For effective immunoaffinity-based exosome iso-
lation, antibodies need to be fixed on a solid surface 
for exosome separation. Over the past few years, 
matrices including chromatography, beads, plates, 
and various types of microfluidic apparatuses have 
been used [13]. Among these, submicron-sized 
magnetic particles (Figure 8), widely used for 
immuno-precipitation of recombinant proteins, have 
been most commonly used. This method not only 
yields high capture efficiency and sensitivity from its 
large surface and near-homogeneous processes, but 
also accommodates large starting sample volumes, 
therefore allowing upscaling or downscaling for 
specific applications [13]. Moreover, as reported, this 
method could be directly transformed to a diagnostic 
platform through the detection of disease-specific 
markers (e.g., EpCAM, CD133, EGFR for cancer cells) 
on the isolated exosomes, facilitated by disease- 
specific antibody and magnetically activated cell sort-
ing [91]. 
 
 
Figure 6. Schematic of Polymer Precipitation Strategy. After the addition of highly hydrophilic polymers to an exosome-containing solution, water molecules 
surrounding the exosomes are tied up by the polymers, lowering the solubility of the exosomes and inducing their subsequent precipitation. The exosomes can be 
easily collected with low-speed centrifugation. 
 
Figure 7. Schematic of aqueous two-phase system-based exosome isolation. When the more hydrophobic polyethylene glycol (PEG) and more 
hydrophilic dextran solutions are mixed, a two-phase system could occur. After addition of PEG and dextran to exosome-containing solutions followed by incubation 
and low-speed centrifugation, proteins and other big molecular complexes preferentially accumulate into PEG while exosomes preferentially accumulate into the 
dextran phase. 
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Figure 8. Schematic of immunoaffinity-based exosome isolation. First, antibodies recognizing exosome-specific markers are immobilized onto solid 
matrices. After incubating exosome-containing fluids with antibody-conjugated solid matrices, exosomes can be enriched onto such solid matrices. Free exosomes 
can be collected via an additional elution step. 
Plates and microchips are also popular matrices 
on which to develop immunoaffinity-based exosome 
separation systems, in addition to the commonly used 
magnetic beads. For example, by using microplate, an 
anti-CD9 antibody-based system has been devised to 
capture and quantify exosomes from various types of 
mediums such as urine and blood [92]. Compared to 
the traditional ultracentrifugation method, this 
microplate-based immunoaffinity capturing device 
performs more efficiently in exosome isolation [92]. 
Requiring only 400 µL of initial plasma sample in a 
one-hour procedure, this method isolates a compar-
able amount of exosome RNAs to that obtained by 
ultracentrifugation of 2.5 mL of plasma in a 16-hour 
procedure [92]. Despite multiple disadvantages such 
as low volume processing capacity and relatively 
lower capture efficiency, this microplate-based meth-
od is suitable for the development of plate reader- 
based real-time diagnostic devices, especially for trace 
amount sample analysis [92]. 
2.5.2 How to maintain the native state of exosomes? A 
major concern for immunoaffinity-based exosome 
isolation 
Even though immunoaffinity-based exosome 
isolation ensures high-purity exosome isolation with 
an easy procedure, the non-neutral pH and non- 
physiological elution buffers (to separate exosomes 
from antibodies) associated with this method could 
irreversibly affect the biological function of the 
collected exosomes. The denatured exosome samples, 
although generally acceptable for diagnosis purposes 
(via assessing genetic and protein contents of exo-
some), are not favorable for exosome-based functional 
studies and various therapeutic applications [89, 93]. 
Great efforts have been made to prepare exosome 
samples with intact structures. In an ingenious study, 
rather than using antibodies, Nakai and colleagues 
designed an exosome isolation device using the Ca2+- 
dependent Tim4 protein, which specifically binds to 
phosphatidylserine, a protein highly expressed on the 
exosome surface [94]. By immobilizing Tim4 proteins 
onto magnetic beads, exosomes with high phospha-
tidylserine expression can be specifically isolated. 
Importantly, since the binding between Tim4 and 
exosomes is strictly dependent on Ca2+ [95], exosomes 
can be easily separated from Tim4-coated beads by 
the removal of Ca2+ through the addition of elution 
buffers containing Ca2+ chelators such as EDTA. 
Under such a gentle Ca2+ chelator treatment, the nat-
ural state of exosomes can be preserved. In another 
case, researchers from the Korea Advanced Institute 
of Science and Technology developed an Exosome- 
specific Dual-patterned Immune-filtration chip for 
specific exosome capture by introducing a chemically 
cleavable linker 3,3'-Dithiobis(sulfosuccinimidyl-
propionate) (DTSSP) between the antibody (anti- 
CD63) and the solid immobilization surface [96]. With 
this method, a simple reduction step via tris-
(2-carboxyethyl) phosphine (TCEP) or Dithiothreitol 
(DTT) cleaves the antibody link to release the exo-
somes for reliable downstream analyses and applica-
tions. Such cleavable link-based antibody immobiliza-
tion methods would be equally eligible to be applied 
to other immobilization matrices such as magnetic 
beads or plates for functional exosome isolation. 
2.5.3 How to isolate total exosomes rather than 
specific exosome groups? Another issue for 
immunoaffinity-based exosome isolation 
Although immunoaffinity allows separation of a 
specific subpopulation of exosomes, at the same time 
it raises concerns about isolation of only the specific 
populations of exosomes that possess the antibody- 
recognized proteins. Considering the vast number of 
heterogeneous properties of exosomes in body fluids, 
this would result in an analytical bias (underestima-
tions and false negatives) [97]. This is especially true 
in cancer diagnosis, where protein expression under-
goes constant modulation with the stage of cancer 
progress [98]. In addition, specific isolation of only a 
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subset of exosomes, although with higher purity, 
results in lower overall yield [39]. 
Taking this into account, apart from protein 
markers, other substances universally expressed on 
exosome membrane have been targeted, such as the 
saccharide chains (e.g., N-linked glycans, alpha-2,6 
sialic acid, mannose, and polylactosamine) over-
expressed on exosomal membranes [99]. In a recent 
exploration, Samsonov and colleagues efficiently iso-
lated exosomes from urine samples via lectin, a type 
of sugar-binding protein displaying high affinity to 
saccharide residues. The composition of these exo-
somes was further confirmed via miRNA profiling to 
be bulk exosomes rather than any particular exosome 
subpopulation [100]. Furthermore, heparin, a type of 
highly sulfated glycosaminoglycan, also holds poten-
tial for total exosome isolation with its ability to non- 
specifically bind to a variety of proteins. As demon-
strated in a recent study [101], heparin-affinity beads 
are capable of harvesting bulk exosomes from not 
only cell culture media but also human plasma, 
following an ultrafiltration step to remove free 
proteins. 
2.5.4 Chemical antibody-based next generation 
immunoaffinity approach 
Even though antibody products possess distinct 
advantages, the high costs related to antibody 
development and production as well as their perisha-
bility significantly compromises their application, 
especially for large scale exosome preparation. To 
counteract these problems, apart from combined 
application with other methods as previously 
suggested [102], another option is to employ cheaper 
and more stable antibody substitutes, such as aptamer 
technologies. Aptamers, which are short single- 
stranded DNA or RNA sequences, can specifically 
recognize and bind to their targets with high affinity 
and specificity in a manner similar to antibodies [103, 
104]. However, unlike traditional antibodies, apta-
mers can be produced by in vitro chemical synthesis 
and exhibit several advantages such as low batch- 
to-batch variation, easy scaling up and down for 
different applications, extended shelf life, low or no 
immunogenicity, low production cost and easy 
chemical modification to improve binding properties 
[105, 106]. Over the past years, several aptamer- 
mediated exosome isolation platforms have been 
developed [107, 108]. Importantly, in addition to 
presenting a practicable option for immunoaffinity- 
based exosome isolation, aptamers also allow the 
preparation of natural exosomes with relatively little 
effort. As known, the recognition of aptamers and 
their target is strictly determined by tertiary structure 
[109, 110] (Figure 9), which in turn is determined by 
various factors such as temperature, ionic strength, as 
well as buffering systems. By adjusting the salt species 
and key ions (e.g., Mg2+ and K2+) to the formation of 
specific three-dimensional structure of aptamers, the 
binding capacity of aptamers can be easily remodu-
lated under mild conditions [109], thereby releasing 
the captured exosomes with native structure and 
intact biological function. 
2.6 Integrated microfluidic technique 
facilitates combinatorial exosome isolation 
and analysis 
By exploring both the physiochemical and bio-
chemical features of exosomes at microscale, the 
dramatic advances in microfabrication technologies 
have offered a valuable opportunity to develop lab- 
on-a-chip-type microfluidic systems for efficient exo-
some isolation [111-113]. Facilitated by existing signal 
detecting platforms, these miniaturized microfluidic 
apparatuses allow for not only fast exosome isolation 
from fingertip amount of body fluids, but also real- 
time exosome characterization for in situ diagnosis 
(Figure 10). Indeed, microfluidic techniques are 
dramatically changing the landscape of exosome- 
based diagnosis by transferring the traditional two- 
step procedure (exosome isolation and characteriza-
tion) to an integrated one-step process [113]. This is 
especially valuable for non-invasive disease detection, 
such as early-stage cancer screening [114, 115]. 
 
 
Figure 9. Aptamer-mediated immunoaffinity. Aptamers recognize and bind their target via conformational complementary. After adjusting key factors of the 
buffering system such as salt types and ionic strength, the shape of the aptamer undergoes change and releases the bound target molecules. 
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Figure 10. Integrated microfluidic technique allows combined exosome isolation and analysis. After adding exosome-containing fluids into the sheath 
medium, particles in the fluids including exosomes can be separated by different approaches based on the physical and biochemical properties of extracellular vesicles. 
Importantly, these miniaturized microfluidic apparatuses, facilitated by signal detecting platforms, allow for not only fast exosome isolation from small amount of body 
fluids, but also real-time exosome characterization for in situ diagnosis. 
 
2.6.1 Immunoaffinity-based microfluidics 
During the past decade, various forms of 
microfluidics have been invented through the explo-
ration of different physiochemical properties of exo-
somes. Among them, the immuno-microfluidic tech-
nique has been most commonly used, resulting in 
commercial microfluidic products (e.g., ExoChip 
[116]). Identical to the commonly used immuno-
affinity-based exosome isolation method, the concept 
behind the immuno-microfluidic-based exosome sep-
aration devices involves the specific recognition of 
exosome markers by corresponding antibodies immo-
bilized on the chips. In 2010, Chen et al. pioneered a 
microfluidic immunoaffinity apparatus for quick exo-
some isolation through the use of an anti-CD63 anti-
body [117]. The resulting device was able to efficiently 
isolate exosomes from as small as 10 µL of cell culture 
medium and serum. Furthermore, by passing 300 µL 
of lysis buffer through the exosome-captured micro-
channel followed by air flushing, the group could 
easily obtain total RNAs from the captured exosomes. 
Subsequent tests demonstrated that significantly 
higher amounts of RNA could be collected via this 
chip system than by directly extracting RNAs from an 
equal amount of serum [117]. Since then, high interest 
has been called toward either improving the efficiency 
or the specificity of such microfluidic-mediated exo-
some isolation systems. 
2.6.1.1 Efforts for immuno-microfluidic-based high-efficient 
exosome isolation 
For a certain channel volume, larger binding 
surface area means more antibody immobilization 
and therefore higher exosome isolation efficiency. 
With this in mind, in 2016, Zhang and colleagues 
developed a microfluidic system that featured a 
graphene oxide/polydopamine (GO/PDA) nano-
interface [118]. The unique features of the 
GO-induced three-dimensional nano-porous struc-
ture provided a higher amount of surface area for 
efficient antibody immobilization and exosome cap-
turing. As demonstrated, the developed CD81 
antibody-microfluidic system not only greatly impro-
ved the efficacy of exosome isolation, but also the 
purity of the resulting exosome samples. Importantly, 
by encapsulating an ultrasensitive ELISA assay with 
both universal exosome biomarkers (CD81 and CD9) 
and cancer-specific biomarkers (EpCAM), this device 
allowed ultrasensitive in situ ovarian cancer detection 
in merely 2 µL of plasma [118]. In another case, to 
increase the capture efficiency of an anti-CD9 
antibody-based immuno-microfluidic chip, Hisey et 
al. introduced the “herringbone groove” (previously 
used to facilitate nanoparticle separation [119]) 
pattern on the ceiling of the microfluidic channels. As 
expected, this novel design ensured significantly 
increased total surface area for antibody immobiliza-
tion, and greatly improved exosome yield. 
2.6.1.2 Efforts for immuno-microfluidic-based highly specific 
exosome isolation 
Nonspecific binding is a big issue for micro-
fluidic-based immunoaffinity isolation as the method 
is incompatible with extra blocking and washing 
steps. This is different than conventional bead- or 
plate- based immunoaffinity approaches, where non-
specific binding between non-exosome vesicles and 
the exosome-specific antibodies (as well as the non-
specific binding between vesicles and the immobili-
zation matrices (e.g., bead or plate surface)) can be 
efficiently eliminated via stringent blocking and 
washing. In recent years, the advances in nano-
technology have provided valuable opportunities to 
address this problem. For instance, Ramanathan et al. 
presented a powerful microfluidic system for high- 
specific exosome capturing and analysis, facilitated by 
the tunable alternating current electrohydrodynamic 
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(ac-EHD) mediated nanoscale lateral fluid flow (also 
known as nano-shearing fluid flow) technique [120]. 
As tested with three different antibodies, including 
anti-prostate specific antigen antibody, anti-CD9 anti-
body, and anti-human epidermal growth factor 
receptor 2 (HER2) antibody, this technology enabled 
efficient elimination of nonspecific/weak bound 
nanoparticles from the immune-affinity sites. Conse-
quently, a greater than three-time increase in the 
sensitivity of exosome detection was recorded comp-
ared to that of traditional lateral flow assay [120]. In 
another example, via employing inertial lift forces to 
effectively and rapidly exchange the washing solution 
around the exosome-antibody binding sites, Dudani 
et.al developed a microfluidic chip featured by a 
“spin-wash” procedure. A high signal-to-noise exo-
some isolation was achieved according to subsequent 
assessment [121]. 
As discussed in Section 1.5, although immuno-
affinity-based exosome isolation allows easy exosome 
isolation, this method is limited by isolation of only 
specific subset of exosomes, high cost, and difficulty 
in maintaining the natural structure of exosomes. 
Size-dependent microfluidic isolation and contact-free 
separation strategies are two types of the most 
successful instances to address this problem. Next, we 
will discuss these two types of instruments to demon-
strate recently developed examples of microfluidic 
devices. 
2.6.2 Size-based microfluidic separation techniques 
facilitate high-quality exosome isolation 
The first size-dependent microfluidic system 
discussed is the well-documented Exosome Total 
Isolation Chip (ExoTIC) [122]. First, up to 10-mL 
solutions were filtered through a 0.22 µm nano- 
porous filter using a syringe pumper. Then, through 
the same syringe pumper and inlet, PBS was applied 
through the nano-porous filter to thoroughly clean 
and recover small extracellular vesicles (including 
exosomes) in a small volume (e.g., 200 µL). In this 
way, ExoTIC can effectively separate exosomes from 
both cell culture media and various types of body 
fluids such as lung bronchoalveolar lavage fluid, 
plasma and urine with limited effect on the native 
structure of exosomes. Importantly, this system was 
able to isolate exosomes from very small sample 
volumes (10–100 μL) with the yield around 4–1000 
times greater than that of ultracentrifugation [122], 
ideal for point-of-care clinical testing. The second 
example is the nanowire-based exosome trip system 
(Figure 11). As demonstrated in Wang’s study [123], 
following a similar principle with SEC, this device is 
characterized by nanowires (made of porous silicon) 
imprinted on the sidewalls of evenly separated 
micropillars to form a nanowire-on-micropillar hier-
archy structure. According to the design, the interval 
between the nanowires can be adjusted from 30 to 200 
nm to physically trap small extracellular vesicles, 
while the sub-micrometer micropillars, apart from 
offering support for nanowire anchoring, are effective 
for removing larger non-exosome particles such as 
cell debris and apoptotic bodies. Furthermore, the 
exosome isolation capacity of this device can be 
further enhanced by pre-loading exosome-specific 
antibodies onto the porous silicon nanowire to 
explore the immunoaffinity-based isolation. As tested, 
this microfluidic device can effectively isolate 40–100 
nm exosome vesicles with a recovery rate of 60%, 
while allowing smaller (e.g., proteins) and large parti-
cles (e.g., cell, cell debris) to pass by unhindered. 
Importantly, via simply incubating in PBS buffer for 
10 min, the chemical etching of the nanowire surface 
could be dissolved, thereby releasing the intact and 
purified exosomes for subsequent applications. 
2.6.3 Contact-free microfluidics–versatile tools for 
future exosome preparation 
In addition to antibody and size-dependent 
microfluidics, rapid developments in microfabrication 
technology have enabled researchers to explore 
contact-free particle sorting mechanisms (e.g., elastic 
lift force, acoustic, and dielectrophoresis), for efficient, 
scalable, and high-quality exosome isolation. 
 
 
Figure 11. Principle of the nanowire-based exosome trip system. (A) Similar to SEC-based separation, a nanowire-on-micropillar hierarchy structure could 
be created via imprinting of porous silicon-consisting nanowires on the walls of the evenly separated micropillars. After adding exosome-containing fluids to the 
nanowire-on-micro-pillar tiered structure, particles in fluids are subject to different fates: (1). Larger particles (e.g., cell) are directly excluded from the 
sub-micrometer micropillar array; (2). Particles with submicron sizes (e.g., cell debris) are able to enter the micropillar interval but are unable to enter the 30–200 nm 
nanowire interval; (3). Small molecules (e.g., proteins) move across the nanowire interval without being obstructed; (4). Particles of 30–200 nm (e.g., exosomes) are 
arrested by the nanowire forest. (B) Particles with different sizes present different retention time and therefore facilitates size-dependent separation. 
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Figure 12. Contact-free microfluidic enables simplified exosome separation procedure. (A) In the viscoelastic medium flow-based microfluidic system, 
the exosome-containing fluids (added from inlet 1) meet the sheath flow (added from inlet 2) and are first aligned along the microchannel wall. After exertion of the 
elastic lift force that arises from viscoelasticity of the fluid, exosomes, and other extracellular components are driven toward the centreline of the microchannel 
according to their sizes, with larger particles eventually reach the centreline. (B) Under the pressure of ultrasound waves, particles with different mechanical 
properties (e.g., compressibility, size and density) experience differential radiation forces and results in contact-free and size-dependent exosome separation in a 
continuous manner. 
 
In recent years, the unique migration pattern of 
particles in non-Newtonian viscoelastic fluids has 
attracted great interests. As documented, the elastic 
lift force created by a viscoelastic medium flow was 
able to control and manipulate the position of 
particles in a size-dependent manner (Figure 12A). 
Indeed, over the past few years, various viscoelastic 
flow-based microfluidic systems have been reported 
to isolate particles ranging from cancer cells, blood 
cells, bacteria, droplets to microspheres [124-126]. In 
2017, a contact-free viscoelastic microfluidic device 
was developed for size-dependent, continuous, and 
label-free exosome separation via manipulation of the 
viscoelastic force applied on exosomes by sheath fluid 
consisting of low concentrated (0.1%) biocompatible 
poly-(oxyethylene) (PEO) [125]. After systematically 
optimizing key factors such as medium elasticity, 
microchannel geometry, and flow speed, this device 
allowed greater than 80% recovery rate and 90% 
purity, which is much higher than the 5%–25% 
recovery rate for ultracentrifugation. Although a size 
cut-off of 200 nm was demonstrated in this work, 
according to the authors, extracellular vesicles of 
defined sizes could be easily obtained by adjusting 
PEO concentration. Amazingly, with the capacity to 
process samples down to 100 μL in a mere 0.1s 
exosome passage time [125], this system holds 
potential to be used as a platform to separate 
exosomes from diverse biological samples for various 
types of theranostic applications. Importantly, 
without a sophisticated microfabrication structure or 
external force field, the contact-free feature of this 
viscoelastic exosome separation system can be conti-
nuously performed, significantly streamlining the 
design and produce of microfluidic-based exosome 
separation systems [127]. 
Under the pressure of ultrasonic waves, particles 
with different mechanical properties (e.g., compressi-
bility, size and density) experience differential radia-
tion forces [128]. Based on this principle, in 2015, Lee 
and colleagues invented an acoustic nano-filter sys-
tem allowing contact-free and size-specific exosome 
separation in a continuous manner [129]. As demon-
strated in Figure 12B, under ultrasound standing 
waves, the larger the particle is, the stronger radiation 
forces it will exert, and therefore display faster migra-
tion toward the pressure nodes, resulting in the sepa-
ration of extracellular vesicles with defined particle 
sizes. When erythrocytes and cell culture medium 
were tested, such size-dependent acoustic technique 
could efficiently isolate purified exosomes [129]. 
Importantly, such acoustic-based device allowed real- 
time control of the “size cut-off” via in situ electronic 
manipulation, which facilitated the isolation of exo-
somes with preferred sizes [129]. In another case, Wu 
and colleagues reported a point-of-care device was 
capable of isolating exosomes from non-pre-treated 
raw blood samples in an automatic manner via the 
integration of microfluidic and acoustic techniques. 
This contact-free device provided the possibility to 
isolate intact, functional exosomes with high yield 
and purity for exosome-related therapeutics, disease 
diagnostics as well as health monitoring [130]. 
In addition to elastic lift force and acoustic force, 
the simplicity of electroactive strategies (without 
using instrumentation and specialized reagents) had 
also been explored for developing contact-free 
exosome isolation microfluidic systems [131]. For 
instance, Davies et al. designed a microfluidic device 
that was able to effectively drive exosomes through a 
membrane while filter out other extracellular vesicles 
via electrophoresis within a microchannel, [132]. To 
further improve electrode-based electrophoresis, 
dielectrophoresis had been employed by generating 
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nonuniform electric fields through inserting insu-
lating posts into the microchannel. After introduction 
to this nonuniform electric field, particles with 
different radii are subject to differing dielectrophor-
esis forces (inversely related to their radius) via pola-
rization effects. Thus, under this electric field, smaller 
particles can be captured by greater gradients of the 
squared electric field (vice versa) and achieve size- 
dependent nanoparticle separation [133]. In 2018, Shi 
et al developed a device based on such a mechanism 
[133]. As reported, this microfluidic system could 
efficiently trap small extracellular vesicles near a glass 
nanopipette tip under 10 V/cm current [133]. In 
another case, glioblastoma-originated exosomes were 
successfully isolated from human plasma in less than 
30 minutes [134]. These works were further improved 
in an effort led by Marczak for simultaneous isolation 
and concentration of exosomes [135]. First, the 
authors developed a transverse local electric field by 
applying an ion-selective membrane. Under this 
electric field, the exosomes in a microfluidic chip 
could be easily forced out of the cross flow. After 
directing the exosome samples to agarose gels to 
eliminate undesirable cell debris, purified exosomes 
with defined particle size could be trapped and 
concentrated by ion-selective membrane. When tested 
with cell culture media and serum, this device was 
able to consistently capture between 60% and 80% of 
exosomes, as assessed by both nanoparticle tracking 
analysis and fluorescence spectroscopy [135]. 
Importantly, with a concentration factor up to 15 ×, 
this device ensured efficient and reliable downstream 
exosome characterization [135]. However, in spite of 
recent progress, additional investigations are still 
needed to further improve the efficacy and reliability 
of this electroactive strategy, especially for the opti-
mal current (alternative current or direct current) and 
biological conditions for different samples. 
2.6.4 Microfluidic devices facilitate real-time exosome 
analysis 
Although the application of exosomes has been 
used in diverse therapeutic purposes such as drug 
delivery, novel cell-free vaccine development and 
regenerative medicine, there has been an emphasis on 
their potential for disease diagnosis, especially in non- 
invasive cancer liquid biopsy [91]. According to our 
statistics, diagnosis represents nearly half (54 in 127) 
of the currently registered exosome-related clinical 
trials (via Clinicaltrials.com). Apart from improving 
separation schedules to isolate high-quality exosomes 
with high yield, the establishment of simple and 
efficient detection techniques represents another 
major task in the development of microfluidic-based 
exosome separation devices. Indeed, in terms of 
exosome-based diagnostic applications, microfluidic 
devices possess multiple advantages for the develop-
ment of low cost, reliable, real-time diagnostic devices 
to process fingertip amounts of easily attainable liquid 
samples such as serum, urine, breast milk, and saliva. 
To facilitate post-separation exosome imaging, 
Ashcroft and colleagues produced a novel immuno- 
microfluidic device featuring a mica channel surface 
[136]. Compare to commonly used glass or polymer 
materials, this antibody-bound mica surface, with a 
distinct atomically flat and hydrophilic surface, could 
be easily separated from the Polydimethylsiloxane 
(PDMS) fabricated flow cell base. This unique design 
thereby allows the attached exosomes and the mica 
surfaces to be directly imaged via ultrahigh-resolution 
atomic force microscopy. In another case, He and 
colleagues introduced an immuno-microchip integra-
ted with ELISA assay as a method of quantitative 
detection. Unlike the traditional immunoaffinity- 
mediated exosome separation strategy, this approach 
allows the direct quantification of both surface and 
intra-vesicular markers of circular exosomes from 30 
μL of plasma sample within 100 min [137]. Later, a 
simplified continuous-flow microfluidic system 
named ExoSearch was developed [138]. Facilitated by 
CD9 antibody (for exosome capture), CA-125 (for 
ELISA detection), EpCAM (for ELISA detection), and 
CD24 antibodies (for ELISA detection), this platform 
enabled rapid exosome isolation and in situ non- 
invasive cancer detection [138]. Later, an anti-CD63 
antibody-based device named ExoChip became 
clinically available [116]. After isolation, exosomes 
collected by ExoChip were stained using a fluorescent 
carbocyanine dye (DiO) prior to plate reader-based 
quantification. Notably, ExoChip has been employed 
as a valuable exosome-mediated diagnostic system for 
various disease screening as it allows fast exosomal 
miRNA profiling [116]. In addition to developing 
miniaturized devices for potable detection, more 
sophisticated detection platforms have also been inte-
grated with current microfluidic systems for advan-
ced applications. For example, Ueda and colleagues 
constructed a simplified microtip device enabling 
rapid and automated exosome isolation from various 
body fluids via conjugation of CD9 antibodies with 
highly porous monolithic silica microtips [139]. By 
further combining this microtip device with a pro-
teome-wide LC/MS/MS platform, the group establi-
shed an exosomal biomarker discovery system that 
could simultaneously analyse up to 12 different sam-
ples. Through this system, the group was able to 
identify a specific antigen of lung cancer-derived exo-
somes, CD91 [139]. 
It should be noted that the analytical sensitivity 
of reported “real-time on-chip exosome analysis” 
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(including detection limit and response time) prima-
rily depends on the specificity and binding capacity of 
the selected antibodies (for ELISA assay) as well as the 
sensitivity and compatibility of the utilized equip-
ment. Therefore, such features of the analytical mod-
ule need to be carefully investigated when designing 
real-time exosome analysis microfluidic devices. 
3. Efficient exosome/microvesicle 
separation is critical for exosome and 
microvesicle-related investigations 
As discussed in Section 1, the basic and applied 
researches of exosomes have been obstructed mainly 
by two issues [11]. One is how to simplify the extrac-
tion procedure and improve the exosome yield; the 
other is how to effectively distinguish exosomes from 
other extracellular vesicles. In recent years, although 
standardized exosome extraction and qualitative/ 
quantitative protocols are still not available, the rapid 
development in separation technology has in a large 
extent solved the problem of exosome isolation. For 
example, in order to obtain a sufficient amount of 
exosomes from cerebrospinal fluid for proteomics and 
nucleic acid quantification studies, researchers prev-
iously needed to collect 200–500 mL of cerebrospinal 
fluid to meet the requirements of ultracentrifugation 
[140]. Nowadays, with newly developed exosome 
separation techniques such as immunoaffinity, chro-
matography and polymer precipitation, 6 mL of cere-
brospinal fluid samples is sufficient to meet quan-
titative requirements [141]. Improvements in the tra-
ditional polymer-based precipitation method have 
also addressed the long-standing obstacle of hydro-
phobic protein interference in urine exosome isolation 
[54]. Today, with commercial exosome isolation kits 
and commonly available molecular biology equip-
ment, exosomes can be extracted from trace amounts 
of clinical samples for subsequent studies in a short 
period of time, which greatly facilitates the basic and 
applied exosome studies. However, the second 
technical problem – how to effectively distinguish 
exosomes from other extracellular vesicles, still pre-
sents a major issue in exosome-related applications. 
We only have to consider the concept of the exosome 
to get an appreciation of what this means. The exo-
some was first proposed in 1987 [3], denoting an 
extracellular vesicle originating from endosomes. It 
should be noted however that the concept of exosome 
is often not used properly in published articles or 
even clinical trials. As shown in Figure 13, apart from 
the endosome-originated exosomes, extracellular 
vesicles also contain a large number of microvesicles 
shed by the cell membrane. Unfortunately, due to 
their similar physicochemical properties and a large 
overlap in particle sizes, effective exosome/micro-
vesicle separation still presents a very difficult task 
[11, 14]. Instead of being inert materials as previously 
assumed, growing evidence is suggesting that micro-
vesicles also display important biological functions 
[142, 143], although many of the published observa-
tions on “exosomes” actually describe the combined 
effects of exosomes and microvesicles. Given our 
limited knowledge of the biofunction of micro-
vesicles, the existence of microvesicles in the tested 
exosome samples inevitably affects the exosome- 
based basic and applied studies in an unpredictable 
manner. As demonstrated by several recent odd 
findings, even for the same cancer cell type, “exo-
somes” collected by different groups could display 
quantitative or even qualitative differences in bio-
logical functions (either tumor promotion or inhibi-
tion) [2]. As suggested, the different proportion of 
exosomes and microvesicles in the tested “exosome” 
samples may be the primary culprit of such 
controversial phenomena. For more accurate and 
reliable exosome-based diagnosis and therapeutic 
applications, an efficient exosome/microvesicle 
separation is necessary. 
3.1 Solely relying on high-specific exosome 
markers is not sufficient for purified exosome 
isolation 
Extracellular vesicles consist of mainly micro-
vesicles and exosomes. In theory, the concentration of 
any component in the extracellular vesicle can be 
achieved by the isolation of another component. In 
practice, efforts aiming at efficient “exosome and 
microvesicle separation” have relied mainly on 
obtaining purified exosomes via identifying highly 
specific exosome biomarkers. This is due to (1) the 
lack of understanding of microvesicles and (2) the 
great potential of exosomes displayed in both basic 
research and theranostic applications in recent years. 
Theoretically, this strategy is feasible as the exosome 
proteins (including nucleic acids) are not a random 
combination of cell fragments but are integrated by a 
strict protein sorting mechanism to maintain their 
stable protein expression [2]. Although current know-
ledge cannot describe in detail this particular sorting 
mechanism, the existence of such a mechanism itself 
provides a basis for the search for exosome-specific 
markers. As mentioned previously, during the past 
decades, various exosome biomarkers such as 
TSG101, CD81, CD9, CD63, CD37, CD82, CHMP2A, 
ALIX, RAB11B, CHMP4B, RAB11A, and RAB5 have 
been tested for immunoaffinity-based exosome Isola-
tion. However, according to experience collected over 
the past 50 years, whether normal cells, stem cells or 
tumor cells, 100% specific markers do not exist [144]; 
even classic exosome markers like CD63 and CD81 
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show expression on other subcellular organs [88] or 
even microvesicles [145, 146]). Taking a step back, if 
the specificity of the employed exosome marker is not 
100% specific (such as the currently used CD81 or 
CD63), then the proportion of microvesicles in the 
residue would not be calculated. Furthermore, under 
this circumstance it is even impossible to estimate the 
proportion of the exosome component. 
In the face of this reality, we believe it is necess-
ary for all scientists engaged in extracellular vesicle- 
related work to consider the following questions: (1) 
Is it a mistake to rely solely on the identification of 
novel exosome markers for exosome and microvesicle 
separation? (2) Are 100% purified exosomes and 
microvesicle components necessary for current basic 
and clinical research? (3) What is the key speed- 
limiting factor for current exosome studies? 
3.2 Impurification is not the real problem for 
exosome-related studies 
Is isolating 100% purified exosomes necessary 
for current exosome studies? In fact, the key obstacle 
facing current exosome studies is not the impurity of 
exosome samples, but the lack of information about 
the proportion of exosomes and microvesicles in the 
collected “exosome” samples. This is understandable. 
From the perspective of exosome-based diagnosis and 
basic investigations, based on enriched exosome 
samples, rational experimental controls and optimiz-
ed statistical models, as long as the composition of the 
studied samples could be accurately determined, the 
reliability of the assays could be ensured. For exam-
ple, in functional studies conducted via siRNA-based 
gene regulation, it is unlikely, and not necessary, to 
completely inhibit the gene of interest. In general, an 
inhibition rate of around 80% is considered sufficient 
for most subsequent investigations. From the pers-
pective of exosome-based drug development, accord-
ing to the current drug approval system of most 
countries (including the United States, the European 
Union, Australia, China, and Japan), unlike the high 
purity required for chemical compounds, the require-
ments for quality control and safety assessment of 
cell-derived compounds such as exosomes can be met 
as soon as (1) the exosome proportion is sufficiently 
high and (2) individual components of the prepara-
tion can be quantified and described [11]. 
Therefore, the key question of current exosome 
studies is how to effectively quantify the individual 
components of the collected exosome samples. How-
ever, we cannot achieve this goal by solely relying on 
exosome markers, as reflected in various immuno-
affinity-based commercial exosome extraction rea-
gents (using antibodies targeting exosome markers). 
Although they claim to be able to enrich exosomes, 
some crucial information, including the proportion 
(or purity) of exosomes in the extract, and the content 
of other components (e.g., microvesicle), is invariably 
absent. Surely, even if a perfect exosome marker with 
100% specificity is available for exosome isolation 
(this would be very unlikely in practice), it still cannot 
guarantee that the remaining vesicles are all micro-
vesicles, which may contain excess exosomes, apop-
totic bodies or protein precipitates. Moreover, in the 
absence of understanding of the microvesicle, we run 
into issues in determining the specificity of the 
employed exosome marker. 
 
 
Figure 13. Extracellular vesicles consist of mainly two types of vesicles with similar physiochemical properties. Extracellular vesicles include exo-
somes and microvesicles. The main differences between them lie in their subcellular origins. Microvesicles are 50–1000 nm shedding particles from cell membrane; 
exosomes are 30–150-nm extracellular vesicles originated from endosomes, they are secreted into body fluids through exocytosis after cell membrane and 
multivesicular body fusion. Due to a lack of effective strategy to separate microvesicle and exosome, it is still difficult to precisely assess their physiochemical 
properties and functions. 
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3.3 Combined application of exosome and 
microvesicle markers for quantitative 
exosome/microvesicle separation 
Since relying on biomarkers of only one compo-
nent (i.e., exosome) cannot yield reliable quantitative 
information of individual components in the extra-
cellular vesicle mixture, it seems that the only feasible 
method is to simultaneously employ both exosome 
and microvesicle markers. In fact, even if the applied 
biomarkers for exosome and microvesicle are not 
100% specific, the respective markers of the two 
components combined with mathematical calculation 
(by Linear Equation in Two Unknowns, Figure 14) 
may present a reliable system to assess the proportion 
of exosomes and microvesicles. At the same time, by 
providing enriched microvesicles with quantitative 
information, the proposed separation system also 
provides opportunities for the investigation of micro-
vesicle-based basic and clinical translations. 
Having specific biological functions [147, 148], 
microvesicles must have stable protein expression. In 
recent years, although several microvesicle markers 
such as annexin A1 [149], CD29 [150], and Sca1 [151] 
have been reported, bona fide markers for micro-
vesicle separation are still not available [152]. Future 
developments in specific microvesicle marker identi-
fication would promote quantitative exosome and 
microvesicle separation. 
4. Perspective 
Over the past few decades, despite the dramatic 
advances made in deciphering the mysteries of exo-
somes, the challenges in efficient exosome isolation 
have yet to be solved. This largely owes to the comp-
lexity of biological fluids, the considerable overlap of 
the physicochemical and biochemical properties 
among the exosomes, lipoproteins, virus, and other 
extracellular vesicles, as well as the heterogeneity of 
exosomes themselves [35]. As a result, no specific 
exosome separation technique has currently been 
accepted as suitable for all studies [153]. Depending 
on the biology samples applied, even the gold stan-
dard ultracentrifugation method often suffers from 
protein and lipoprotein contaminants. Under these 
circumstances, the combined application of two or 
more techniques presents a plausible strategy for 
efficient exosome isolation, as demonstrated by the 
previously reported combined use of immunoaffinity- 
based exosome capture (or ultrafiltration) and den-
sity-gradient centrifugation [96, 154, 155]. 
 
 
Figure 14. Calculation of the proportion of exosome and microvesicle components of extracellular vesicles via exosome and microvesicle marker-specific 
antibodies. The extracellular vesicles A (A’) were concentrated via polymer precipitation. Then exosomes (B) or microvesicles (B’) were extracted using 
corresponding antibody-based immunoaffinity capture; after elution, exosomes (C’) and microvesicles (C) were extracted again from the elutes using antibody-based 
immunoaffinity method. Then, the extracted exosomes (B, C’) and microvesicles (B’, C) were quantified. The proportion of exosome and microvesicle in the original 
extracellular vesicles was calculated using the formulation as shown in D. 
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However, it should be noted that although 
combined isolation techniques result in higher exo-
some purity, they often increase procedure cost and 
complexity, thus resulting in reduced overall yield 
and unreliable downstream analysis. Therefore, the 
nature of the samples as well as the purpose of the 
investigation needs to be carefully considered when a 
particular combination of techniques is selected. For 
example, when the immunoaffinity capture method 
was used to process large volume samples, a pre- 
treatment via polymer precipitation [156] may be 
beneficial, to both promote the efficacy of the anti-
body-based exosome separation and avoid using 
excessive quantities of expensive antibodies. 
For both diagnosis and therapeutic applications, 
researchers should carefully consider the strengths 
and weaknesses of the accessible strategies. As dis-
cussed previously, immunoaffinity capture promises 
selective isolation of highly purified exosomes of 
specific origins, or even subpopulations of exosomes 
from biological fluids. Therefore, in cases where diag-
nosis is scheduled for the subsequent investigations, 
immunoaffinity may present the most sensitive and 
specific method. Unfortunately, the current immuno-
affinity method is compromised heavily by the lack of 
reliable markers for exosome isolation [17]. Further-
more, when considering the heterogeneity in antigen 
expression, especially in cancer cells, the possibility of 
underestimation and false negatives must be noted 
[153]. Even so, with the identification of more disease- 
specific exosome markers, coupled with recently 
developed microfabrication technologies (e.g., micro-
fluidic), immunoaffinity-based exosome isolation may 
contribute greatly to future diseases diagnosis, espe-
cially through non-invasive liquid biopsy. Further-
more, as discussed in Section 3, isolation of specific 
exosome markers (as well as microvesicle markers) is 
also of great value to address the long-standing issue 
of quantitative exosome/microvesicle separation. 
On the other hand, the therapeutic applications 
of exosomes are limited by the lack of an effective 
method to isolate high-quality exosomes in bulk [157, 
158]. In all likelihood, the ultrafiltration method may 
contribute most to this area due to its advantageous 
features, including ease of handling and analyzing 
large batches of biological samples, and capability of 
isolating exosomes with high purity and defined 
sizes. However, despite increasing popularity, ultra-
filtration is not without its limitations, especially the 
problem of membrane clogging and vesicle trapping. 
This results in not only reduced lifetime of the expen-
sive membranes, but also reduced isolation efficiency 
and erroneous interpretations of test results. Fortun-
ately, this issue can be addressed by tangential flow 
filtration. Although current tangential flow filtration 
techniques are still limited by processing volume, 
given the ongoing progress in hydromechanics and 
material sciences, we believe the isolation efficiency of 
future ultrafiltration methods will be dramatically 
improved. Similarly, SEC, which features both high- 
quality exosome preparation and excellent repro-
ducibility, also holds great potential for high- 
throughput industrial applications. This is especially 
true given the fact that the gravity flow used in SEC 
causes minimal damage to exosome structure and 
function. Collectively, we reckon that ultrafiltration 
and SEC may provide a basis for future standardiza-
tion of clinical grade exosome samples. 
Conversely, no microfluidic device has been 
readily applied in clinical applications, in spite of the 
remarkable advances achieved in recent years. Major 
roadblocks to clinical applications include 
standardization, scalability, and validation [127, 159]. 
Furthermore, the relatively low isolation efficiency of 
such methods may pose detrimental effects on 
downstream assessments such as genomic and 
proteomic analysis, and result in compromised diag-
nosis results. We believe further improvements in 
microfluidic processing capacity via multiple exo-
some sorting mechanisms, as well as massively 
parallel microfluidic sets, represents plausible solu-
tions. Importantly, most of the existing exosome 
isolation techniques are applied to basic research. For 
microfluidics to become more clinically relevant we 
suggest the design of techniques and devices for 
exosome isolation should take a more translational 
approach, by thoroughly evaluating a sufficient 
number of clinical samples for improved selectivity, 
robustness, and sensitivity. 
Furthermore, to facilitate the in-depth investiga-
tion of exosomes and their related biological func-
tions, more efforts need to be made for the develop-
ment of simultaneous exosome separation/quanti-
fication strategies and devices, to achieve not only 
efficient exosome isolation, but also real-time exo-
some quantification and analysis. Although several 
real-time exosome isolation/detection apparatuses 
have been reported, standardizing the analysis mod-
ule for comparable and reliable readouts still repre-
sents a great challenge. In fact, compared to analysis, 
development of standardized exosome isolation 
methods constitutes an even harder task. Due to the 
heterogeneous features of biological samples, a 
reliable exosome separation technique suitable for 
every study is still not available. A bespoke selection 
of separation methods tailored for particular 
exosome-containing objects is imperative for high- 
quality exosome isolation and readout validation. As 
a result, future efforts may need to develop different 
exosome isolation standards to meet the particular 
Theranostics 2020, Vol. 10, Issue 8 
 
 
http://www.thno.org 
3704 
properties of different types of biological samples and 
target particles (i.e., genetic or protein contents) to be 
screened. 
5. Conclusion 
The observation of exosome-mediated cell 
signaling provides a great opportunity for developing 
exosome-related basic and applied biomedical 
applications in various fields. Despite the revolution-
ary progress in exosome-based theranostic applica-
tions over the past few decades, there are still funda-
mental unanswered questions in the field. These 
questions address some of the hotspots of current bio-
medical research such as the secretory regulation 
mechanism of exosomes, exosomal content sorting 
mechanism and their intercellular transduction path-
way. Various exosome separation strategies and 
devices have been suggested to facilitate the investi-
gation of exosomes and their related biological func-
tions. As comprehensively discussed in this work, 
standardization in exosome preparation such as 
specimen handling, isolation, and quantification has 
still not been established. Through studying the 
nature of particular samples and specific application 
settings, we believe careful selection of isolation tech-
niques (or a combination of isolation techniques) will 
help investigators address many of the challenges 
faced in current exosome studies. In addition, we also 
believe that the exosome/microvesicle separation and 
quantification strategy (using both exosome and 
microvesicle markers) as suggested in this work can 
provide a plausible strategy to obtain accurate 
quantitative information for future exosome (and 
microvesicle)-related investigations. 
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